IRCT20200105046010N59招募中未知
In- Vivo Bioequivalence study of Abiraterone tablet 250 mg Sobhan Oncology Pharma (Abiraterone ® 250 mg Tab.) with brand drug (ZYTIGA® 250 mg, Janssen Biotech, Germany) in Iranian healthy volunteers.
Sobhan Oncology Pharmaceutical CO.0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-60 years old
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Abiraterone tablet 500 mg Actero Middle East with brand drug (ZYTIGA® 500 mg, Janssen Biotech, Germany)Bio equivalence test.IRCT20200105046010N57Actero middle east Pharm Co.24
招募中
不适用
In-vivo Bioequivalence Test of Abiraterone tablets with brand drug (ZYTIGA® 500 mg, Janssen Biotech, Germany)Bio equivalence test.IRCT20200105046010N55anoalvand Pharmaceutical Co24
招募中
Unknown
Bioequivalence study of Abirateron 500mg tabletIRCT20200105046010N87Tabriz University of Medical Sciences24
招募中
不适用
Eplerenone tablet 50mg Abourayhan (Alderon 50mg),In-Vivo Bioequivalence in iranian healthy volunteerIn this study the bioequivalence of test and brand of Esmoprazole will evaluated..IRCT20200105046010N2Aburayhan Pharmaceutical Co.24
已完成
2 期
Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)NCT04862091Jiangsu HengRui Medicine Co., Ltd.69